Research programme: monoclonal antibody therapeutics - Tetragenetics/argenx /Crystal Bioscience/Sevion Therapeutics
Latest Information Update: 02 Mar 2017
At a glance
- Originator arGEN-X; Crystal Bioscience; Sevion Therapeutics; Tetragenetics
- Developer argenx; Crystal Bioscience; Sevion Therapeutics; Tetragenetics
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Ion channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders